{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:13:08Z","timestamp":1761988388026,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jcpo.2022.100368","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T09:34:16Z","timestamp":1668418456000},"page":"100368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Quality-of-life reporting in randomized controlled trials shaping the EAU Renal Cell Carcinoma Guidelines"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3186-8657","authenticated-orcid":false,"given":"Nuno","family":"Dias","sequence":"first","affiliation":[]},{"given":"Sara","family":"Meireles","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Pina-Vaz","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Abreu-Mendes","sequence":"additional","affiliation":[]},{"given":"Francisco","family":"Botelho","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.jcpo.2022.100368_bib1","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.annonc.2022.04.007","article-title":"The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO clinical practice guideline","volume":"33","author":"Di Maio","year":"2022","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.jcpo.2022.100368_bib2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jcpo.2022.100368_bib3","unstructured":"EMA Guideline on the evaluation of anticancer medicinal products in man EMA\/CHMP\/29246\/2014, Appendix 2. Available online: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/other\/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf\u3009, (Accessed 1st April 2022)."},{"key":"10.1016\/j.jcpo.2022.100368_bib4","unstructured":"US FDA, Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims, 2009. Available online: \u3008https:\/\/www.fda.gov\/media\/77832\/download\u3009, (Accessed 1st April 2022)."},{"key":"10.1016\/j.jcpo.2022.100368_bib5","doi-asserted-by":"crossref","unstructured":"B. Ljungberg, L. Albiges, Y. Abu-Ghanem, J. Bedke, U. Capitanio, S. Dabestani, S. Fernandez-Pello, R.H. Giles, F. Hofmann, M. Hora, T. Klatte, T. Kuusk, T.B. Lam, L. Marconi, T. Powles, R. Tahbaz, A. Volpe, A. Bex, European Association of Urology guidelines on renal cell carcinoma: the 2022 update, Eur. Urol., vol. 82(no. 4), 2022, pp. 399\u2013410.","DOI":"10.1016\/j.eururo.2022.03.006"},{"issue":"25","key":"10.1016\/j.jcpo.2022.100368_bib6","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1200\/JCO.22.00868","article-title":"Management of metastatic clear cell renal cell carcinoma: ASCO guideline","volume":"40","author":"Rathmell","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.jcpo.2022.100368_bib7","first-page":"740","article-title":"Impact of adoption of patient-reported outcomes in clinical practice on the accuracy of symptom reporting in medical records of cancer patients","volume":"111","author":"Marino","year":"2020","journal-title":"Recent. Prog. Med."},{"issue":"3","key":"10.1016\/j.jcpo.2022.100368_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0363","article-title":"Patient experience captured by quality-of-life measurement in oncology clinical trials","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.jcpo.2022.100368_bib9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.euf.2019.02.020","article-title":"Patient-reported outcome measures in metastatic urinary cancers","volume":"6","author":"Bergerot","year":"2020","journal-title":"Eur. Urol. Focus"},{"issue":"6","key":"10.1016\/j.jcpo.2022.100368_bib10","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.euf.2019.10.014","article-title":"Distress and quality of life among patients with advanced genitourinary cancers","volume":"6","author":"Bergerot","year":"2020","journal-title":"Eur. Urol. Focus"},{"issue":"2","key":"10.1016\/j.jcpo.2022.100368_bib11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/jmrs.421","article-title":"A review of the barriers to using Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs) in routine cancer care","volume":"68","author":"Nguyen","year":"2021","journal-title":"J. Med. Radiat. Sci."},{"issue":"11","key":"10.1016\/j.jcpo.2022.100368_bib12","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/jnci\/djz038","article-title":"Systematic evaluation of patient-reported outcome protocol content and reporting in cancer trials","volume":"111","author":"Kyte","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.jcpo.2022.100368_bib13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.2017.21903","article-title":"Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension","volume":"319","author":"Calvert","year":"2018","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.jcpo.2022.100368_bib14","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"issue":"9 Suppl. 10","key":"10.1016\/j.jcpo.2022.100368_bib15","first-page":"S133","article-title":"Assessing quality of life in research and clinical practice","volume":"16","author":"Jacobsen","year":"2002","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.jcpo.2022.100368_bib16","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.2018.18085","article-title":"Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer","volume":"321","author":"Denis","year":"2019","journal-title":"JAMA"}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538322000479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538322000479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:08:57Z","timestamp":1761988137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538322000479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":16,"alternative-id":["S2213538322000479"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2022.100368","relation":{},"ISSN":["2213-5383"],"issn-type":[{"type":"print","value":"2213-5383"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality-of-life reporting in randomized controlled trials shaping the EAU Renal Cell Carcinoma Guidelines","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2022.100368","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100368"}}